Back to top
more

Phibro Animal Health (PAHC)

(Real Time Quote from BATS)

$25.34 USD

25.34
200,063

+1.49 (6.25%)

Updated Nov 11, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Phibro (PAHC) Q2 Earnings Surpass Estimates, 2022 View Up

by Zacks Equity Research

Phibro (PAHC) reports better-than-expected earnings for the fiscal second quarter. Robust performances by the Animal Health and Mineral Health segments drove the top line.

Here's Why You Should Retain Phibro (PAHC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.

Phirbo's (PAHC) Rising Costs, Currency Headwind Ail Growth

by Zacks Equity Research

Though Phirbo (PAHC) has raised prices on selective products, these increases do not fully compensate for the higher cost of freight and labor materials.

Phibro (PAHC) Down 12.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic

by Zacks Equity Research

Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.

Phirbo (PAHC) Q1 Earnings Lag Estimates, Revenue View Up

by Zacks Equity Research

Phirbo's (PAHC) year-over-year increase in Q1 sales is primarily due to stronger international demand for poultry and cattle products and more robust growth in the nutritional specialties and vaccine product lines.

Petco (WOOF) Down 26% This Year So Far: What Should You Do?

by Zacks Equity Research

Petco (WOOF) with its omni-channel distribution and a well-diversified product offering is strongly placed in the pet care industry, which is growing rapidly.

Why Is Phibro (PAHC) Down 6.1% Since Last Earnings Report?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sapna Bagaria headshot

Hold Petco (WOOF) as It Rides on Continued Demand for Pet Care

by Sapna Bagaria

Petco (WOOF) by dint of its wide product and services portfolio, omni-channel presence and strategic initiatives is well poised to cash in on the expanding petcare industry.

Phibro (PAHC) Q4 Earnings Match Estimates, Margins Down

by Zacks Equity Research

Phibro (PAHC) sees revenue growth in fourth-quarter fiscal 2021 due to strength in all three segments.

Phibro (PAHC) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Mineral Nutrition and Performance Products is expected to have contributed to Phibro's (PAHC) fourth-quarter fiscal 2021 performance.

Petco (WOOF) Q2 Earnings Beat on Continued Demand for Pet Care

by Zacks Equity Research

Petco (WOOF) Q2 earnings exceed estimates on buoyant demand for pet care products and services.

PAHC vs. ABT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PAHC vs. ABT: Which Stock Is the Better Value Option?

Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.

Trina Mukherjee headshot

Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD

by Trina Mukherjee

Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.

Here's Why You Should Buy National Vision (EYE) Stock Now

by Zacks Equity Research

Investors remain optimistic about National Vision (EYE) on increased eyeglass comparable demand and encouraging 2021 strategies.

Riya Anand headshot

Pandemic Boosts Animal Health Spending: 4 Stocks to Buy

by Riya Anand

Stocks like PetIQ (PETQ), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC) and Zoetis (ZTS) offering animal health products and services make great picks for long term.

PAHC vs. ABT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PAHC vs. ABT: Which Stock Is the Better Value Option?

Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and bullish 2021 earnings guidance.

Illumina's (ILMN) NovaSeq Adoption Aids, Margin Woe Stays

by Zacks Equity Research

Illumina (ILMN) derives benefits from the cascading effect of the ACOG guidance on increasing coverage of NIPT for all pregnancies.

Hologic (HOLX) to Beat Post-COVID Woes With Mobidiag Buyout

by Zacks Equity Research

Hologic (HOLX) management believes that Mobidiag has created a differentiated platform that deals with many of the historical challenges faced in multiplexed point-of-care molecular testing.

Riya Anand headshot

3 Discounted MedTech Stocks Poised for Sturdy Growth in 2021

by Riya Anand

Fundamentally-sound stocks like Henry Schein (HSIC), UnitedHealth Group (UNH) and Phibro Animal Health (PAHC) are trading at a discount and make great picks for the long term.

ResMed (RMD) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.

CVS Health (CVS) Digital Tools Gain Steam Amid COVID-19 Crisis

by Zacks Equity Research

CVS Health's (CVS) consumer-centric digital strategy is more relevant in the current environment as people are increasingly using technology while staying indoors.

Bruker (BRKR) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on solid CALID Group growth potential and raised 2021 financial guidance.